Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tarceva Advisory Committee To Focus On Treatment Alternatives, Subgroup Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

ODAC will review currently available treatment options and negative treatment effects in subgroups as OSI seeks to expand Tarceva's indication to first-line maintenance and monotherapy in NSCLC.

You may also be interested in...



Will Maintenance Sell In NSCLC? Experts Weigh Costs Against Benefits

Longer-term "maintenance" therapy may be the new frontier for oncology products as cancer evolves into a chronic, manageable disease – a shift that will provide benefits for patients and the pharmaceutical industry. But as cancer drug costs continue to skyrocket and cost-effectiveness discussions become more commonplace, that transition may not come as smoothly as industry would like.

Will Maintenance Sell In NSCLC? Experts Weigh Costs Against Benefits

Longer-term "maintenance" therapy may be the new frontier for oncology products as cancer evolves into a chronic, manageable disease – a shift that will provide benefits for patients and the pharmaceutical industry. But as cancer drug costs continue to skyrocket and cost-effectiveness discussions become more commonplace, that transition may not come as smoothly as industry would like.

Tarceva Gets Thumbs Down For NSCLC: Cmte. Seeks Better Subgroup Analysis

The Oncologic Drugs Advisory Committee's rejection of OSI Pharmaceutical's Tarceva as maintenance therapy for non-small cell lung cancer seems an example of the increasingly specialized and intense nature of drug development: the panel wanted bigger, larger studies with more subgroup analyses

Related Content

Topics

UsernamePublicRestriction

Register

OM005224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel